Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Report 2026
Download Free Sample Buy Now
Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Global Report 2026 Market Report Infographic Image
Item added to cart!

Published : February 2026

Pages :

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Purchase This Report Download Sample PDF
Purchase This Report

Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Report 2026

Global Outlook – By Treatment (Drug, Therapy), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), By End-User (Hospitals, Specialty Clinics, Homecare, Other End-User) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview

• Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment market size has reached to $3.18 billion in 2025

• Expected to grow to $8.6 billion in 2030 at a compound annual growth rate (CAGR) of 22%

• Growth Driver: Rising Obesity Prevalence Driving Growth In The Market

• Market Trend: Innovative MASH Treatments Address Fibrosis And Improve Liver Health Outcomes

• North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?

Metabolic dysfunction-associated steatohepatitis (MASH) treatment refers to medical and lifestyle interventions aimed at addressing inflammation and liver damage caused by fat accumulation in the liver associated with metabolic dysfunctions like obesity, diabetes, and insulin resistance, focusing on improving liver health and metabolic outcomes.

The main treatments in metabolic dysfunction-associated steatohepatitis (MASH) treatment are drug and therapy. Drug treatment refers to the use of pharmaceutical therapies aimed at reducing liver inflammation, fibrosis, and fat accumulation associated with the condition, with the goal of improving liver function and preventing disease progression. The end users of this are hospitals, specialty clinics, homecare, and others, and are distributed by various channels such as hospital pharmacies, online pharmacies, and retail pharmacies.

Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Global Report 2026 Market Report bar graph

What Is The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Size and Share 2026?

The metabolic dysfunction-associated steatohepatitis (mash) treatment market size has grown exponentially in recent years. It will grow from $3.18 billion in 2025 to $3.88 billion in 2026 at a compound annual growth rate (CAGR) of 22.2%. The growth in the historic period can be attributed to rising prevalence of obesity, increasing incidence of type 2 diabetes, growing awareness of liver health disorders, expansion of diagnostic testing capabilities, early adoption of lifestyle modification programs.

What Is The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Growth Forecast?

The metabolic dysfunction-associated steatohepatitis (mash) treatment market size is expected to see exponential growth in the next few years. It will grow to $8.6 billion in 2030 at a compound annual growth rate (CAGR) of 22.0%. The growth in the forecast period can be attributed to increasing adoption of glp-1 agonists, growth in antifibrotic drug development, rising penetration of digital liver monitoring tools, expansion of bariatric surgery usage, increasing focus on personalized metabolic therapies. Major trends in the forecast period include expansion of precision liver disease therapeutics, AI-enabled early detection and risk stratification, cloud-based liver health data management, iot-integrated lifestyle and medication monitoring, growth in sustainable and preventive metabolic health programs.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Segmentation

1) By Treatment: Drug, Therapy

2) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

3) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-User

Subsegments:

1) By Drug: Antifibrotic Agents, Antidiabetic Drugs, Lipid-Lowering Agents, Vitamin E, Obeticholic Acid (OCA), GLP-1 Agonists

2) By Therapy: Pharmacotherapy, Lifestyle Modifications (Dietary Changes, Exercise), Bariatric Surgery, Liver Transplantation

What Is The Driver Of The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?

The increasing prevalence of obesity is expected to propel the growth of the metabolic dysfunction-associated steatohepatitis (MASH) treatment market going forward. Obesity is a medical condition characterized by an excessive accumulation of body fat that can negatively impact overall health, typically measured by a body mass index (BMI) of 30 or higher. The prevalence of obesity is rising globally, driven by sedentary lifestyles, unhealthy diets, and metabolic risk factors. Metabolic Dysfunction-Associated Steatohepatitis (MASH) treatment in obesity focuses on addressing insulin resistance, reducing liver fat, and improving metabolic health through lifestyle changes and targeted therapies. For instance, in March 2023, according to the World Heart Foundation, a Switzerland-based non-government global cardiovascular community, Currently, approximately 2.3 billion adults and children worldwide are obese or overweight, and with the ongoing obesity trend, this number is projected to reach 2.7 billion by 2025. Therefore, the increasing prevalence of obesity is driving growth in the metabolic dysfunction-associated steatohepatitis (MASH) treatment industry.

Key Players In The Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

Major companies operating in the metabolic dysfunction-associated steatohepatitis (mash) treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, Novartis AG, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Apollo Health and Lifestyle Limited, Jenny Craig, Nutrisystem, Madrigal Pharmaceuticals, Anoos Clinic, Galectin Therapeutics Inc., Galmed Pharmaceuticals, Hepion Pharmaceuticals, Inventiva, NGM Biopharmaceuticals, Sagimet Biosciences, Viking Therapeutics, Terns Pharma, Genfit SA

Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Trends and Insights

Major companies operating in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market are focusing on developing innovative products such as liver fibrosis treatment solutions to provide the treatment option for patients with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to severe liver fibrosis. Liver fibrosis treatment solutions focus on addressing the underlying causes of liver damage through lifestyle modifications, antiviral medications, and emerging antifibrotic therapies, aiming to halt or reverse the progression of fibrosis and improve liver function. For instance, in March 2024, Madrigal Pharmaceuticals, Inc., a US-based biopharmaceutical company, announced the FDA approval of Rezdiffra (resmetirom), the first-ever treatment for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to severe liver fibrosis. Rezdiffra is a daily oral tablet that demonstrated efficacy in resolving MASH without worsening fibrosis and improving liver fibrosis in phase 3 clinical trials. This breakthrough offers a non-invasive treatment alternative, eliminating the need for liver biopsies, and significantly improves patient access and outcomes in managing fatty liver disease.

Need data on a specific region in this market?
Request Regional Data

What Are Latest Mergers And Acquisitions In The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?

In January 2024, Suzhou Ribo Life Science Co., Ltd., a China-based clinical-stage company, and Ribocure Pharmaceuticals AB (Ribo), a Sweden-based clinical-stage biotechnology company, announced a collaboration with Boehringer Ingelheim for $2 billion. This partnership aims to develop innovative treatments for nonalcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH) by combining Ribo’s RNAi therapeutic platform with Boehringer Ingelheim’s expertise in cardiovascular, renal, and metabolic diseases. The collaboration focuses on addressing the urgent need for effective therapies to halt NASH progression and restore liver function. Boehringer Ingelheim is a Germany-based pharmaceutical company actively involved in developing treatments for metabolic dysfunction-associated steatohepatitis (MASH).

Regional Outlook

North America was the largest region in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?

The metabolic dysfunction-associated steatohepatitis (MASH) treatment market consists of revenues earned by entities by providing services such as clinical care services, nutritional counseling, pharmacotherapy management, patient education, and support programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The metabolic dysfunction-associated steatohepatitis (MASH) treatment market also includes sales of antioxidants, antidiabetic drugs, and liver protective supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Report 2026?

The metabolic dysfunction-associated steatohepatitis (mash) treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the metabolic dysfunction-associated steatohepatitis (mash) treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abdul Wasay

Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2026 $3.88 billion
Revenue Forecast In 2035 $8.6 billion
Growth Rate CAGR of 22.2% from 2026 to 2035
Base Year For Estimation 2025
Actual Estimates/Historical Data 2020-2025
Forecast Period 2026 - 2030 - 2035
Market Representation Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered Treatment, Distribution Channel, End-User
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, Novartis AG, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Apollo Health and Lifestyle Limited, Jenny Craig, Nutrisystem, Madrigal Pharmaceuticals, Anoos Clinic, Galectin Therapeutics Inc., Galmed Pharmaceuticals, Hepion Pharmaceuticals, Inventiva, NGM Biopharmaceuticals, Sagimet Biosciences, Viking Therapeutics, Terns Pharma, Genfit SA
Customization ScopeRequest for Customization
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Artificial Intelligence & Autonomous Intelligence

4.1.3 Digitalization, Cloud, Big Data & Cybersecurity

4.1.4 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems

4.1.5 Sustainability, Climate Tech & Circular Economy

4.2. Major Trends

4.2.1 Expansion Of Precision Liver Disease Therapeutics

4.2.2 Ai-Enabled Early Detection And Risk Stratification

4.2.3 Cloud-Based Liver Health Data Management

4.2.4 Iot-Integrated Lifestyle And Medication Monitoring

4.2.5 Growth In Sustainable And Preventive Metabolic Health Programs

5. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Specialty Clinics

5.3 Homecare

5.4 Diagnostic Centers

5.5 Research Institutes

6. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Size, Comparisons And Growth Rate Analysis

7.3. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Segmentation

9.1. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Drug, Therapy

9.2. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

9.3. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospitals, Specialty Clinics, Homecare, Other End-User

9.4. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Sub-Segmentation Of Drug, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Antifibrotic Agents, Antidiabetic Drugs, Lipid-Lowering Agents, Vitamin E, Obeticholic Acid (OCA), GLP-1 Agonists

9.5. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Sub-Segmentation Of Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Pharmacotherapy, Lifestyle Modifications (Dietary Changes, Exercise), Bariatric Surgery, Liver Transplantation

10. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Regional And Country Analysis

10.1. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

11.1. Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

12.1. China Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

13.1. India Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

14.1. Japan Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

14.2. Japan Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

15.1. Australia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

16.1. Indonesia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

17.1. South Korea Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

17.2. South Korea Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

18.1. Taiwan Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

18.2. Taiwan Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

19.1. South East Asia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

19.2. South East Asia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

20.1. Western Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

20.2. Western Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

21.1. UK Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

22.1. Germany Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

23.1. France Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

24.1. Italy Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

25.1. Spain Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

26.1. Eastern Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

26.2. Eastern Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

27.1. Russia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

28.1. North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

28.2. North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

29.1. USA Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

29.2. USA Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

30.1. Canada Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

30.2. Canada Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

31.1. South America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

31.2. South America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

32.1. Brazil Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

33.1. Middle East Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

33.2. Middle East Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

34.1. Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

34.2. Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Regulatory and Investment Landscape

36. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Competitive Landscape And Company Profiles

36.1. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Company Profiles

36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

36.3.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.4. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

36.3.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

37. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Other Major And Innovative Companies

Novartis AG, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Apollo Health and Lifestyle Limited, Jenny Craig, Nutrisystem, Madrigal Pharmaceuticals, Anoos Clinic, Galectin Therapeutics Inc., Galmed Pharmaceuticals, Hepion Pharmaceuticals, Inventiva, NGM Biopharmaceuticals

38. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

40. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market High Potential Countries, Segments and Strategies

40.1 Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market In 2030 - Countries Offering Most New Opportunities

40.2 Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market In 2030 - Segments Offering Most New Opportunities

40.3 Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Overview Of Key Products - Product Examples
  • Table 2: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Attractiveness, Factor-Wise Evaluation
  • Table 3: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Supply Chain Analysis
  • Table 4: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Major Raw Material Providers
  • Table 5: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Major Resource Providers
  • Table 6: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Major Manufacturers (Suppliers)
  • Table 7: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Major Distributors And Channel Partners
  • Table 8: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Key Technologies & Future Trends
  • Table 9: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Major Trends
  • Table 10: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Major End Users
  • Table 11: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Table 12: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Historic Market Growth, 2020-2025, $ Billion
  • Table 13: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Table 14: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market - TAM, US$ Billion, 2025
  • Table 15: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 16: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 17: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 18: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Sub-Segmentation Of Drug, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 19: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Sub-Segmentation Of Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 20: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 21: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 22: Asia-Pacific, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 23: Asia-Pacific, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 24: Asia-Pacific, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 25: China, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 26: China, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 27: China, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 28: India, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 29: India, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 30: India, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 31: Japan, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 32: Japan, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 33: Japan, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 34: Australia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 35: Australia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 36: Australia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 37: Indonesia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 38: Indonesia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 39: Indonesia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 40: South Korea, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 41: South Korea, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 42: South Korea, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 43: Taiwan, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 44: Taiwan, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 45: Taiwan, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 46: South East Asia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 47: South East Asia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 48: South East Asia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 49: Western Europe, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 50: Western Europe, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 51: Western Europe, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 52: UK, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 53: UK, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 54: UK, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 55: Germany, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 56: Germany, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 57: Germany, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 58: France, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 59: France, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 60: France, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 61: Italy, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 62: Italy, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 63: Italy, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 64: Spain, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 65: Spain, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 66: Spain, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 67: Eastern Europe, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 68: Eastern Europe, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 69: Eastern Europe, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 70: Russia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 71: Russia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 72: Russia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 73: North America, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 74: North America, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 75: North America, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 76: USA, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 77: USA, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 78: USA, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 79: Canada, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 80: Canada, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 81: Canada, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 82: South America, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 83: South America, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 84: South America, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 85: Brazil, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 86: Brazil, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 87: Brazil, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 88: Middle East, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 89: Middle East, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 90: Middle East, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 91: Africa, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 92: Africa, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 93: Africa, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 94: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Table 95: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market - Company Scoring Matrix
  • Table 96: Pfizer Inc. Financial Performance
  • Table 97: Johnson & Johnson Financial Performance
  • Table 98: Merck & Co. Inc. Financial Performance
  • Table 99: Sanofi SA Financial Performance
  • Table 100: AstraZeneca PLC Financial Performance
  • Table 101: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Competitive Benchmarking (In USD Billions)
  • Table 102: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Competitive Dashboard
  • Table 103: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Table 104: Global, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Size Gain ($ Billion), Segmentation By Treatment, 2025 – 2030
  • Table 105: Global, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030
  • Table 106: Global, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Size Gain ($ Billion), Segmentation By End-User, 2025 – 2030

List Of Figures

    Figure 1: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Overview Of Key Products - Product Examples
  • Figure 2: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Attractiveness, Factor-Wise Evaluation
  • Figure 3: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Supply Chain Analysis
  • Figure 4: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Major Raw Material Providers
  • Figure 5: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Major Resource Providers
  • Figure 6: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Major Manufacturers (Suppliers)
  • Figure 7: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Major Distributors And Channel Partners
  • Figure 8: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Key Technologies & Future Trends
  • Figure 9: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Major Trends
  • Figure 10: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Major End Users
  • Figure 11: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Figure 12: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Historic Market Growth, 2020-2025, $ Billion
  • Figure 13: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Figure 14: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market - TAM, US$ Billion, 2025
  • Figure 15: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 16: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 17: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 18: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Sub-Segmentation Of Drug, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 19: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Sub-Segmentation Of Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 20: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 21: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 22: Asia-Pacific, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 23: Asia-Pacific, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 24: Asia-Pacific, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 25: China, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 26: China, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 27: China, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 28: India, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 29: India, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 30: India, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 31: Japan, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 32: Japan, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 33: Japan, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 34: Australia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 35: Australia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 36: Australia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 37: Indonesia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 38: Indonesia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 39: Indonesia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 40: South Korea, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 41: South Korea, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 42: South Korea, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 43: Taiwan, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 44: Taiwan, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 45: Taiwan, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 46: South East Asia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 47: South East Asia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 48: South East Asia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 49: Western Europe, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 50: Western Europe, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 51: Western Europe, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 52: UK, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 53: UK, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 54: UK, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 55: Germany, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 56: Germany, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 57: Germany, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 58: France, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 59: France, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 60: France, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 61: Italy, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 62: Italy, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 63: Italy, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 64: Spain, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 65: Spain, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 66: Spain, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 67: Eastern Europe, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 68: Eastern Europe, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 69: Eastern Europe, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 70: Russia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 71: Russia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 72: Russia, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 73: North America, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 74: North America, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 75: North America, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 76: USA, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 77: USA, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 78: USA, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 79: Canada, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 80: Canada, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 81: Canada, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 82: South America, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 83: South America, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 84: South America, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 85: Brazil, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 86: Brazil, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 87: Brazil, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 88: Middle East, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 89: Middle East, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 90: Middle East, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 91: Africa, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 92: Africa, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 93: Africa, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 94: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Figure 95: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market - Company Scoring Matrix
  • Figure 96: Pfizer Inc. Financial Performance
  • Figure 97: Johnson & Johnson Financial Performance
  • Figure 98: Merck & Co. Inc. Financial Performance
  • Figure 99: Sanofi SA Financial Performance
  • Figure 100: AstraZeneca PLC Financial Performance
  • Figure 101: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Competitive Benchmarking (In USD Billions)
  • Figure 102: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Competitive Dashboard
  • Figure 103: Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Figure 104: Global, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Size Gain ($ Billion), Segmentation By Treatment, 2025 – 2030
  • Figure 105: Global, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030
  • Figure 106: Global, Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Size Gain ($ Billion), Segmentation By End-User, 2025 – 2030

Strategic Report on Gender Reassignment Surgery Market: Growth Opportunities and Emerging Challenges

Read More About Strategic Report on Gender Reassignment Surgery Market: Growth Opportunities and Emerging Challenges

In-Depth Health Check-Up Market Report: Business Trends, Growth Factors, and Forecast to 2029

Read More About In-Depth Health Check-Up Market Report: Business Trends, Growth Factors, and Forecast to 2029

Global Insights: Healthcare Digital Experience Platform Market Expected to Surpass $4.34 Billion by 2029

Read More About Global Insights: Healthcare Digital Experience Platform Market Expected to Surpass $4.34 Billion by 2029

2025 Healthcare Information Technology (IT) Outsourcing Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Read More About 2025 Healthcare Information Technology (IT) Outsourcing Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

Read More About A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

Read More About A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

A 2025 strategic report on market size, competitive landscape and expansion strategies in the medications for heart failure market.

Read More About A 2025 strategic report on market size, competitive landscape and expansion strategies in the medications for heart failure market.

Explore strategic insights and forecasts in the global virtual nutrition coach app market, offering competitive benchmarking and market growth trends.

Read More About Explore strategic insights and forecasts in the global virtual nutrition coach app market, offering competitive benchmarking and market growth trends.

Metabolic Disorders Drugs Global Market Report 2022 – By Type (Anti Diabetics drugs, Anti-Thyroid Drugs, Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)), By Distribution Channel (Hospital Pharmacies, Retai...

Liver Metastases Treatment Market Report 2026 - Global Outlook – By Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy), By Primary Cancer (Colorectal Cancer, Breast Cancer), By Distribution Channel (Hospital ...

Liver Diseases Therapeutics Market Report 2026 - Global Outlook – By Disease Type (Hepatitis, Non-Alcoholic Fatty Liver Disease, Alcohol-Induced, Liver Cancer ), By Treatment (Antiviral, Chemotherapy, Immunosuppressive A...

Peptide Based Metabolic Disorders Therapeutics Market Report 2026 - Global Outlook – By Drug Type (Liraglutide, Exenatide, Other Drug Type), By Application (Lysosomal Storage Diseases, Diabetes, Obesity, Hypercholesterol...

Non-Alcoholic Steatohepatitis Treatment Market Report 2026 - Global Outlook – By Drug Type (Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types), By Test Ty...

Non-Alcoholic Steatohepatitis Treatment Market Report 2026 - Global Outlook – By Drug Type (Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types), By Test Ty...

Non-Alcoholic Steatohepatitis Biomarkers Market Report 2026 - Global Outlook – By Type (Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Other Types), By Technology (Enzym...

Fatty Liver Treatment Market Report 2026 - Global Outlook – By Treatment Type (Anti-Viral Drugs, Chemotherapy Drugs, Targeted Therapy, Anti-Fibrotic Drugs), By Disease Type (Hepatitis, Liver Cancer, Non-Alcoholic Fatty L...

Frequently Asked Questions

The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment market was valued at $3.18 billion in 2025, increased to $3.88 billion in 2026, and is projected to reach $8.6 billion by 2030.

The global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment market is expected to grow at a CAGR of 22.0% from 2026 to 2035 to reach $8.6 billion by 2035.

Some Key Players in the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment market Include, Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, Novartis AG, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Apollo Health and Lifestyle Limited, Jenny Craig, Nutrisystem, Madrigal Pharmaceuticals, Anoos Clinic, Galectin Therapeutics Inc., Galmed Pharmaceuticals, Hepion Pharmaceuticals, Inventiva, NGM Biopharmaceuticals, Sagimet Biosciences, Viking Therapeutics, Terns Pharma, Genfit SA .

Major trend in this market includes: Innovative MASH Treatments Address Fibrosis And Improve Liver Health Outcomes. For further insights on this market. request a sample here

North America was the largest region in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metabolic dysfunction-associated steatohepatitis (mash) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us